DK382986D0 - Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor - Google Patents

Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor

Info

Publication number
DK382986D0
DK382986D0 DK382986A DK382986A DK382986D0 DK 382986 D0 DK382986 D0 DK 382986D0 DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A DK 382986 D0 DK382986 D0 DK 382986D0
Authority
DK
Denmark
Prior art keywords
granulocyte
stimulating factor
colony stimulating
macrophag
macrophage colony
Prior art date
Application number
DK382986A
Other languages
English (en)
Other versions
DK174603B1 (da
DK382986A (da
Inventor
Dirk M Anderson
Michael A Cantrell
Douglas P Cerretti
Iii Paul J Conlon
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27117812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK382986(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK382986D0 publication Critical patent/DK382986D0/da
Publication of DK382986A publication Critical patent/DK382986A/da
Application granted granted Critical
Publication of DK174603B1 publication Critical patent/DK174603B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK198603829A 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet DK174603B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76689385A 1985-08-16 1985-08-16
US76689385 1985-08-16
US06/888,995 US5078996A (en) 1985-08-16 1986-07-31 Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US88899586 1986-07-31

Publications (3)

Publication Number Publication Date
DK382986D0 true DK382986D0 (da) 1986-08-11
DK382986A DK382986A (da) 1987-02-17
DK174603B1 DK174603B1 (da) 2003-07-14

Family

ID=27117812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198603829A DK174603B1 (da) 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet

Country Status (8)

Country Link
US (1) US5078996A (da)
EP (1) EP0211684B1 (da)
JP (1) JPH0780781B2 (da)
AT (1) ATE77958T1 (da)
AU (1) AU586876B2 (da)
CA (1) CA1341142C (da)
DE (1) DE3685918T2 (da)
DK (1) DK174603B1 (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130493C1 (ru) * 1984-07-06 1999-05-20 Новартис Аг Способ получения белка с активностью gm-csf приматов
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5093115A (en) 1985-06-11 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing activated killer monocytes for treating colorectal cancer
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
WO1989004173A1 (en) * 1987-11-12 1989-05-18 Schering Corporation Acceleration of bone formation with gm-csf
BE1002141A5 (fr) * 1988-01-13 1990-07-31 Bartholeyns Jacques Procede de culture et d'activation de cellules humaines et conditionnement pour le traitement du cancer.
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
WO1990001942A1 (en) * 1988-08-19 1990-03-08 Genetics Institute, Inc. Treatment for malignant melanoma
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5178855A (en) * 1989-01-30 1993-01-12 Schering Corporation Treatment of luekocyte dysfunction with GM-CSF
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US6001351A (en) * 1993-05-18 1999-12-14 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
CA2163218C (en) * 1993-05-18 2002-09-10 Mohamed Chokri New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6540994B1 (en) * 1997-07-18 2003-04-01 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
EP0871458B1 (en) * 1995-07-21 2002-11-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
KR20010080384A (ko) * 1998-11-03 2001-08-22 스티븐 에이. 서윈. 엠.디. 암 관련 항원 및 이의 동정 방법
ATE516046T1 (de) 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
KR20030064377A (ko) * 2000-08-11 2003-07-31 파브릴, 인크. Ｔ 세포 매개 병증을 개선시키기 위한 방법 및 조성물
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
IL158328A0 (en) * 2001-04-13 2004-05-12 Wyeth Corp Surface proteins of streptococcus pyogenes
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
BR0208944A (pt) 2001-04-16 2006-10-10 Wyeth Corp quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN100593544C (zh) * 2002-03-15 2010-03-10 惠氏控股有限公司 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
EP3064215A1 (en) 2002-10-16 2016-09-07 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
EA009559B1 (ru) 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
AU2005222607B2 (en) * 2004-03-15 2010-11-25 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ATE491475T1 (de) * 2004-07-16 2011-01-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
EP1802335A2 (en) 2004-10-21 2007-07-04 Wyeth a Corporation of the State of Delaware Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20080193376A1 (en) * 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US9868961B2 (en) 2006-03-30 2018-01-16 The Regents Of The University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
PT2041270E (pt) 2006-07-13 2013-12-27 Wyeth Llc Produção de glicoproteínas
ES2541546T3 (es) * 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
EP2094279B1 (en) * 2006-11-15 2015-01-07 Eli Lilly and Company Methods and compositions for treating influenza
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
MX2009009240A (es) * 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
US8530428B2 (en) * 2007-03-07 2013-09-10 Mayo Foundation For Medical Education And Research Treating cancer with granulocyte-macrophage colony stimulating factor
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
WO2008124102A2 (en) * 2007-04-06 2008-10-16 Cell Genesys Inc. Ara-c in combination with a cytokine-secreting cell and use thereof
US20090028857A1 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
US20090175906A1 (en) * 2007-12-21 2009-07-09 Wyeth Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
RU2536981C9 (ru) 2009-06-22 2015-05-10 ВАЙЕТ ЭлЭлСи Иммуногенные композиции антигенов staphylococcus aureus
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
EP2335730A1 (en) 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
PL3150222T3 (pl) 2010-12-22 2020-05-18 Wyeth Llc Stabilne immunogenne kompozycje antygenów staphylococcus aureus
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
US9724366B2 (en) 2012-12-30 2017-08-08 Carmel-Haifa University Economic Corporation Ltd CD11 B[low] macrophages and conditioned media thereof for treating cancer and/or fibrosis
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US20160008449A1 (en) 2013-03-15 2016-01-14 Zoetis Services Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3116539B1 (en) 2014-03-11 2018-10-10 Regents of the University of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
MX2017011648A (es) 2015-03-12 2017-11-02 Zoetis Services Llc Metodos de piolisina y composiciones.
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
JP6675484B2 (ja) 2015-08-14 2020-04-01 ゾエティス・サービシーズ・エルエルシー マイコプラズマ・ボビス組成物
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
JP2019533995A (ja) 2016-10-05 2019-11-28 ゾエティス・サービシーズ・エルエルシー 強力な生ワクチンとして使用するための安定に脱水された原生動物を提供する凍結乾燥方法
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
US20230321212A1 (en) 2020-08-26 2023-10-12 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4241791A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Combined gene and radio therapy for the treatment of cancer
EP4241790A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expression system for the treatment of cancer
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPS59137417A (ja) * 1983-01-28 1984-08-07 Morinaga Milk Ind Co Ltd 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
IE59581B1 (en) * 1984-11-20 1994-03-09 Schering Biotech Corp Cdna clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
ATE77958T1 (de) 1992-07-15
DK174603B1 (da) 2003-07-14
DK382986A (da) 1987-02-17
EP0211684A2 (en) 1987-02-25
AU6103186A (en) 1987-02-19
EP0211684B1 (en) 1992-07-08
DE3685918T2 (de) 1993-02-04
DE3685918D1 (de) 1992-08-13
CA1341142C (en) 2000-11-21
AU586876B2 (en) 1989-07-27
EP0211684A3 (en) 1988-06-08
JPS6289621A (ja) 1987-04-24
US5078996A (en) 1992-01-07
JPH0780781B2 (ja) 1995-08-30

Similar Documents

Publication Publication Date Title
DK382986A (da) Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor
Hiltz et al. α-MSH peptides inhibit acute inflammation induced in mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
NO880929D0 (no) Produksjon og bruk av il-6.
KR100313064B1 (ko) C-키트수용체의리간드및그의사용방법
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
Hideo et al. Production of an interleukin-8-like chemokine by cytokine-stimulated rat NRK-49F fibroblasts and its suppression by anti-inflammatory steroids
Soma et al. Biological Activities of Novel Recombinant Tumor Necrosis Factor Having N-Terminal: Amino Acid Sequences Derived from Cytotoxic Factors Produced by THP-1 Cells
Rathjen et al. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
RU94022481A (ru) Способ определения иммуногенной активности биоактивных соединений и состав для его осуществления
Morita et al. lnterleukin-8 Production from Cultured Human Dermal Fibroblasts by Stimulation with Supernatant of Cultured Human Epidermal Cells
Yip et al. Stimulation of lymphokine production by teleocidin, aplysiatoxin, and debromoaplysiatoxin
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
EP0502599A1 (en) Use of IL-4 to enhance the reparitive phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
MY107071A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Hornicek et al. Production and partial characterization of interleukin 2 induced by periodic acid oxidation of lymphocyte membranes
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
IT1212658B (it) Procedimento per la purificazione di una sostanza fisiologicamente attiva avente attivita antitumorale
Iwasaka et al. Antitumor activities of human recombinant Interferon‐γ against cervical tumor transplanted into nude mice
Johnson et al. Connective tissue-activating peptide III (CTAP-III): cloning the synthetic gene and characterization of the protein expressed in E. coli
Fujikawa et al. Augmentation of depressed lymphokine activated killer activity by continuous intravenous-administration of recombinant interleukin 2 to patients with hepatocellular carcinoma
DE68918197D1 (de) Methode zur Herstellung von rekombinantem menschlichem beta-Interleukin-1 in homogener Form.

Legal Events

Date Code Title Description
PUP Patent expired